Final Count Shows Bigger Oversubscription in Medivir's New Share Issue
03 juin 2004 03h09 HE
|
Medivir
HUDDINGE, Sweden, June 3, 2004 (PRIMEZONE) -- The final count for Medivir's new share issue shows that 4,263,695 B shares, corresponding to 99.16 percent of those offered, were subscribed through the...
Medivir's New Share Issue Oversubscribed
28 mai 2004 03h04 HE
|
Medivir
HUDDINGE, Sweden, May 28, 2004 (PRIMEZONE) -- Following the close of the subscription period for Medivir's new share issue for SEK 322.5m, preliminary figures indicate subscription for slightly more...
Principal Medivir Shareholders Place Subscription Rights
13 mai 2004 02h59 HE
|
Medivir
HUDDINGE, Sweden, May 13, 2004 (PRIMEZONE) -- Bo Oberg, Nils-Gunnar Johansson and certain of their colleagues at Medivir have sold a total of 1,062,285 subscription rights to Handelsbanken Capital...
Medivir Interim Report Jan. 1 -- March 31, 2004
22 avr. 2004 06h52 HE
|
Medivir
HUDDINGE, Sweden, April 22, 2004 (PRIMEZONE) -- The Board of Medivir AB decided on 15 March 2004 to conduct a new share issue of approximately SEK 322m. The decision is conditional on approval by the...
EU Patent Granted on Medivir's Herpes Project ME-609
31 mars 2004 02h24 HE
|
Medivir
HUDDINGE, Sweden, March 31, 2004 (PRIMEZONE) -- The European Patent Office today granted a patent on Medivir's herpes project ME-609. Medivir currently has operational responsibility for development...
Medivir's MIV-150 presented at Microbicides 2004 in London
30 mars 2004 07h34 HE
|
Medivir
HUDDINGE, Sweden, March 30, 2004 (PRIMEZONE) -- At the Microbicides 2004 International Congress in London, Medivir and The Population Council presented preclinical results from a combination of...
Medivir: Cathepsin S Research Programme Designates Candidate Drug (CD)
29 mars 2004 04h19 HE
|
Medivir
HUDDINGE, Sweden, March 29, 2004 (PRIMEZONE) -- Medivir and Peptimmune jointly announce today that an orally active, small molecule inhibitor of the protease enzyme Cathepsin S has been selected as a...
SEK 322m rights issue in Medivir
16 mars 2004 02h49 HE
|
Medivir
HUDDINGE, Sweden, March 16, 2004 (PRIMEZONE) -- Medivir:
- Major progress has recently been made in two of Medivir's late pre-clinical projects, Cathepsin S (inflammatory diseases) and Cathepsin K...
Medivir Financial Statement 1 Jan-31 Dec 2003
17 févr. 2004 07h56 HE
|
Medivir
HUDDINGE, Sweden, Feb. 17, 2004 (PRIMEZONE) --
-- MIV-310 was outlicensed to Boehringer Ingelheim in July in a global licensing agreement with a total contract value of Eur 122 m.
-- MIV-210 was...
Nucleoside analogue reverse transcriptase inhibitor 204937 (MIV-210) presented at GlaxoSmithKline R&D-day
05 déc. 2003 03h34 HE
|
Medivir
HUDDINGE, Sweden, Dec. 05, 2003 (PRIMEZONE) -- GlaxoSmithKline (GSK) and Medivir entered a licensing agreement for MIV- 210 a nucleoside analogue reverse transcriptase inhibitor (NRTI), in May 2003....